Literature DB >> 35385861

FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation.

Caroline Junqueira1,2,3, Ângela Crespo4,5, Shahin Ranjbar4,6, Luna B de Lacerda4,5,7, Mercedes Lewandrowski4,5, Jacob Ingber4,5, Blair Parry8, Sagi Ravid4,5, Sarah Clark9, Marie Rose Schrimpf4,5, Felicia Ho4,5, Caroline Beakes8, Justin Margolin8, Nicole Russell8, Kyle Kays8, Julie Boucau10, Upasana Das Adhikari10, Setu M Vora4,11, Valerie Leger12, Lee Gehrke9,12, Lauren A Henderson5,13, Erin Janssen5,13, Douglas Kwon10, Chris Sander14, Jonathan Abraham9, Marcia B Goldberg9,15, Hao Wu4,5,12, Gautam Mehta16,17, Steven Bell18, Anne E Goldfeld4,6, Michael R Filbin19, Judy Lieberman20,21.   

Abstract

SARS-CoV-2 can cause acute respiratory distress and death in some patients1. Although severe COVID-19 is linked to substantial inflammation, how SARS-CoV-2 triggers inflammation is not clear2. Monocytes and macrophages are sentinel cells that sense invasive infection to form inflammasomes that activate caspase-1 and gasdermin D, leading to inflammatory death (pyroptosis) and the release of potent inflammatory mediators3. Here we show that about 6% of blood monocytes of patients with COVID-19 are infected with SARS-CoV-2. Monocyte infection depends on the uptake of antibody-opsonized virus by Fcγ receptors. The plasma of vaccine recipients does not promote antibody-dependent monocyte infection. SARS-CoV-2 begins to replicate in monocytes, but infection is aborted, and infectious virus is not detected in the supernatants of cultures of infected monocytes. Instead, infected cells undergo pyroptosis mediated by activation of NLRP3 and AIM2 inflammasomes, caspase-1 and gasdermin D. Moreover, tissue-resident macrophages, but not infected epithelial and endothelial cells, from lung autopsies from patients with COVID-19 have activated inflammasomes. Taken together, these findings suggest that antibody-mediated SARS-CoV-2 uptake by monocytes and macrophages triggers inflammatory cell death that aborts the production of infectious virus but causes systemic inflammation that contributes to COVID-19 pathogenesis.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35385861     DOI: 10.1038/s41586-022-04702-4

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  48 in total

1.  Aging immunity may exacerbate COVID-19.

Authors:  Arne N Akbar; Derek W Gilroy
Journal:  Science       Date:  2020-07-17       Impact factor: 47.728

2.  Antibody responses to SARS-CoV-2 in patients with COVID-19.

Authors:  Quan-Xin Long; Bai-Zhong Liu; Hai-Jun Deng; Gui-Cheng Wu; Kun Deng; Yao-Kai Chen; Pu Liao; Jing-Fu Qiu; Yong Lin; Xue-Fei Cai; De-Qiang Wang; Yuan Hu; Ji-Hua Ren; Ni Tang; Yin-Yin Xu; Li-Hua Yu; Zhan Mo; Fang Gong; Xiao-Li Zhang; Wen-Guang Tian; Li Hu; Xian-Xiang Zhang; Jiang-Lin Xiang; Hong-Xin Du; Hua-Wen Liu; Chun-Hui Lang; Xiao-He Luo; Shao-Bo Wu; Xiao-Ping Cui; Zheng Zhou; Man-Man Zhu; Jing Wang; Cheng-Jun Xue; Xiao-Feng Li; Li Wang; Zhi-Jie Li; Kun Wang; Chang-Chun Niu; Qing-Jun Yang; Xiao-Jun Tang; Yong Zhang; Xia-Mao Liu; Jin-Jing Li; De-Chun Zhang; Fan Zhang; Ping Liu; Jun Yuan; Qin Li; Jie-Li Hu; Juan Chen; Ai-Long Huang
Journal:  Nat Med       Date:  2020-04-29       Impact factor: 53.440

Review 3.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Authors:  Charles A Dinarello
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

4.  An inflammatory cytokine signature predicts COVID-19 severity and survival.

Authors:  Diane Marie Del Valle; Seunghee Kim-Schulze; Hsin-Hui Huang; Noam D Beckmann; Sharon Nirenberg; Bo Wang; Yonit Lavin; Talia H Swartz; Deepu Madduri; Aryeh Stock; Thomas U Marron; Hui Xie; Manishkumar Patel; Kevin Tuballes; Oliver Van Oekelen; Adeeb Rahman; Patricia Kovatch; Judith A Aberg; Eric Schadt; Sundar Jagannath; Madhu Mazumdar; Alexander W Charney; Adolfo Firpo-Betancourt; Damodara Rao Mendu; Jeffrey Jhang; David Reich; Keith Sigel; Carlos Cordon-Cardo; Marc Feldmann; Samir Parekh; Miriam Merad; Sacha Gnjatic
Journal:  Nat Med       Date:  2020-08-24       Impact factor: 53.440

5.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.

Authors:  Chaomin Wu; Xiaoyan Chen; Yanping Cai; Jia'an Xia; Xing Zhou; Sha Xu; Hanping Huang; Li Zhang; Xia Zhou; Chunling Du; Yuye Zhang; Juan Song; Sijiao Wang; Yencheng Chao; Zeyong Yang; Jie Xu; Xin Zhou; Dechang Chen; Weining Xiong; Lei Xu; Feng Zhou; Jinjun Jiang; Chunxue Bai; Junhua Zheng; Yuanlin Song
Journal:  JAMA Intern Med       Date:  2020-07-01       Impact factor: 21.873

6.  Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients.

Authors:  Tamara S Rodrigues; Keyla S G de Sá; Adriene Y Ishimoto; Amanda Becerra; Samuel Oliveira; Leticia Almeida; Augusto V Gonçalves; Debora B Perucello; Warrison A Andrade; Ricardo Castro; Flavio P Veras; Juliana E Toller-Kawahisa; Daniele C Nascimento; Mikhael H F de Lima; Camila M S Silva; Diego B Caetite; Ronaldo B Martins; Italo A Castro; Marjorie C Pontelli; Fabio C de Barros; Natália B do Amaral; Marcela C Giannini; Letícia P Bonjorno; Maria Isabel F Lopes; Rodrigo C Santana; Fernando C Vilar; Maria Auxiliadora-Martins; Rodrigo Luppino-Assad; Sergio C L de Almeida; Fabiola R de Oliveira; Sabrina S Batah; Li Siyuan; Maira N Benatti; Thiago M Cunha; José C Alves-Filho; Fernando Q Cunha; Larissa D Cunha; Fabiani G Frantz; Tiana Kohlsdorf; Alexandre T Fabro; Eurico Arruda; Renê D R de Oliveira; Paulo Louzada-Junior; Dario S Zamboni
Journal:  J Exp Med       Date:  2021-03-01       Impact factor: 14.307

7.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.

Authors:  Jérôme Hadjadj; Nader Yatim; Darragh Duffy; Frédéric Rieux-Laucat; Solen Kernéis; Benjamin Terrier; Laura Barnabei; Aurélien Corneau; Jeremy Boussier; Nikaïa Smith; Hélène Péré; Bruno Charbit; Vincent Bondet; Camille Chenevier-Gobeaux; Paul Breillat; Nicolas Carlier; Rémy Gauzit; Caroline Morbieu; Frédéric Pène; Nathalie Marin; Nicolas Roche; Tali-Anne Szwebel; Sarah H Merkling; Jean-Marc Treluyer; David Veyer; Luc Mouthon; Catherine Blanc; Pierre-Louis Tharaux; Flore Rozenberg; Alain Fischer
Journal:  Science       Date:  2020-07-13       Impact factor: 47.728

Review 8.  Channelling inflammation: gasdermins in physiology and disease.

Authors:  Xing Liu; Shiyu Xia; Zhibin Zhang; Hao Wu; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2021-03-10       Impact factor: 112.288

Review 9.  Inflammasome activation at the crux of severe COVID-19.

Authors:  Setu M Vora; Judy Lieberman; Hao Wu
Journal:  Nat Rev Immunol       Date:  2021-08-09       Impact factor: 53.106

Review 10.  Characteristics of SARS-CoV-2 and COVID-19.

Authors:  Ben Hu; Hua Guo; Peng Zhou; Zheng-Li Shi
Journal:  Nat Rev Microbiol       Date:  2020-10-06       Impact factor: 78.297

View more
  57 in total

1.  What triggers severe COVID? Infected immune cells hold clues.

Authors:  Smriti Mallapaty
Journal:  Nature       Date:  2022-04       Impact factor: 49.962

Review 2.  The humoral response and antibodies against SARS-CoV-2 infection.

Authors:  Hai Qi; Linqi Zhang; Bo Liu; Xinquan Wang
Journal:  Nat Immunol       Date:  2022-06-27       Impact factor: 31.250

3.  Epigenetic profiling linked to multisystem inflammatory syndrome in children (MIS-C): A multicenter, retrospective study.

Authors:  Veronica Davalos; Carlos A García-Prieto; Gerardo Ferrer; Sergio Aguilera-Albesa; Juan Valencia-Ramos; Agustí Rodríguez-Palmero; Montserrat Ruiz; Laura Planas-Serra; Iolanda Jordan; Iosune Alegría; Patricia Flores-Pérez; Verónica Cantarín; Victoria Fumadó; Maria Teresa Viadero; Carlos Rodrigo; Maria Méndez-Hernández; Eduardo López-Granados; Roger Colobran; Jacques G Rivière; Pere Soler-Palacín; Aurora Pujol; Manel Esteller
Journal:  EClinicalMedicine       Date:  2022-06-25

Review 4.  Gasdermins: New Therapeutic Targets in Host Defense, Inflammatory Diseases, and Cancer.

Authors:  Laura Magnani; Mariasilvia Colantuoni; Alessandra Mortellaro
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 5.  Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.

Authors:  Shuai Xia; Lijue Wang; Yun Zhu; Lu Lu; Shibo Jiang
Journal:  Signal Transduct Target Ther       Date:  2022-07-19

6.  IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes.

Authors:  Jose L Garrido; Matías A Medina; Felipe Bravo; Sarah McGee; Francisco Fuentes-Villalobos; Mario Calvo; Yazmin Pinos; James W Bowman; Christopher D Bahl; Maria Ines Barria; Rebecca A Brachman; Raymond A Alvarez
Journal:  Cell Rep       Date:  2022-05-16       Impact factor: 9.995

Review 7.  Immune response in COVID-19: what is next?

Authors:  Qing Li; Ying Wang; Qiang Sun; Jasmin Knopf; Martin Herrmann; Liangyu Lin; Jingting Jiang; Changshun Shao; Peishan Li; Xiaozhou He; Fei Hua; Zubiao Niu; Chaobing Ma; Yichao Zhu; Giuseppe Ippolito; Mauro Piacentini; Jerome Estaquier; Sonia Melino; Felix Daniel Weiss; Emanuele Andreano; Eicke Latz; Joachim L Schultze; Rino Rappuoli; Alberto Mantovani; Tak Wah Mak; Gerry Melino; Yufang Shi
Journal:  Cell Death Differ       Date:  2022-05-17       Impact factor: 12.067

Review 8.  Antibody-mediated neutralization of SARS-CoV-2.

Authors:  Henning Gruell; Kanika Vanshylla; Timm Weber; Christopher O Barnes; Christoph Kreer; Florian Klein
Journal:  Immunity       Date:  2022-05-13       Impact factor: 43.474

9.  Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.

Authors: 
Journal:  Lancet Respir Med       Date:  2022-07-08       Impact factor: 102.642

10.  Immediate myeloid depot for SARS-CoV-2 in the human lung.

Authors:  Mélia Magnen; Ran You; Arjun A Rao; Ryan T Davis; Lauren Rodriguez; Camille R Simoneau; Lisiena Hysenaj; Kenneth H Hu; Christina Love; Prescott G Woodruff; David J Erle; Carolyn M Hendrickson; Carolyn S Calfee; Michael A Matthay; Jeroen P Roose; Anita Sil; Melanie Ott; Charles R Langelier; Matthew F Krummel; Mark R Looney
Journal:  bioRxiv       Date:  2022-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.